Investigational entrectinib: What you need to know

What is entrectinib?

Entrectinib (RXDX-101) is an investigational, next generation oral medicine in development for the treatment of locally advanced or metastatic solid tumours that harbour ROS1 or NTRK 1/2/3 fusions. It is a potent, selective central nervous system (CNS)-active tyrosine kinase inhibitor (TKI) currently under investigation in a phase II basket study to assess whether it could be an effective treatment for shrinking tumours across a broad range of cancers harbouring ROS1 or NTRK positive gene fusions. It is a once-daily treatment that, if approved, will provide a new option for people with life-threatening NTRK and ROS1 fusion-positive tumours, for which there are currently limited non-invasive therapeutic options.

What are ROS1 and NTRK gene fusions?

ROS1 and NTRK gene fusions are a specific type of rearrangements which can, ultimately, cause signalling malfunctions. These malfunctions cause cells to grow and proliferate in an uncontrolled manner, resulting in cancer. These cancers can occur at various sites in the body, with ROS1 occurring more frequently in non-small cell lung cancer (NSCLC) and NTRK occurring in many locations, including cholangiocarcinoma, colorectal, gynaecological, neuroendocrine, NSCLC, salivary gland, pancreatic, sarcoma and thyroid cancers. ROS1 gene fusions occur in 1-2% of NSCLC, while NTRK gene fusions have been identified in a broad range of solid tumour types.

How does entrectinib work?

Entrectinib is designed to inhibit kinase activity of the TRK A/B/C and ROS1 proteins, whose activating fusions cause cells to grow and proliferate in certain rare cancer populations. Importantly, entrectinib can cross the blood-brain barrier (BBB), a semi-permeable membrane that controls the entry of cells and molecules to the brain and central nervous system. This means that entrectinib can target tumours that have metastasised to the CNS, a common site of progression in ROS1-positive NSCLC patients. Currently, there are limited effective non-invasive therapeutic options for patients with these gene fusions. Next-generation sequencing is required to identify individuals most likely to benefit from tumour-agnostic entrectinib.
What is the latest clinical evidence for entrectinib?

Results from an integrated analysis of three studies, including the global phase II STARTRK-2 basket study, showed that entrectinib shrank tumours in people with locally advanced or metastatic ROS1 fusion-positive NSCLC and in individuals with NTRK fusion-positive tumours across ten different solid tumour types:

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>ROS1 fusion-positive NSCLC</th>
<th>NTRK fusion-positive cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective response rate (ORR)</td>
<td>77.4%</td>
<td>57.4%</td>
</tr>
<tr>
<td>Duration of response (DOR)</td>
<td>Median of 24.6 months</td>
<td>Median of 10.4 months</td>
</tr>
<tr>
<td>Intracranial response (IC ORR)</td>
<td>55%</td>
<td>54.5%, with more than a quarter of these patients having a complete response</td>
</tr>
</tbody>
</table>

The safety profile of entrectinib was consistent with that seen in previous analyses.
What is the clinical significance of entrectinib?

Since entrectinib targets ROS1 and NTRK fusion-positive tumours across a range of rare cancers and also impacts CNS metastases, once approved, it can provide an additional, much-needed treatment option for patients with these gene fusions. Many patients on the standard treatment for ROS1-positive NSCLC with CNS disease at the time of diagnosis relapse within one year of starting therapy.9 There is also a high unmet need for effective, safe and well tolerated treatments for people who have tumours which have spread to the CNS; more than 30% of individuals with ROS1-positive NSCLC have CNS metastases.10

What is the value of this latest entrectinib data for Roche?

Entrectinib is the latest breakthrough in Roche’s oncology portfolio of targeted medicines aimed at advancing the personalisation of cancer treatment. This innovation brings together cutting-edge technology, precision medicine, and genomic profiling, paving the way even further to personalised approaches to healthcare, and reinforcing Roche’s position as a leading innovator in precision medicine. Entrectinib has been granted Breakthrough Therapy Designation (BTD) by the US FDA; Priority Medicines (PRIME) designation by the EMA; and the Sakigake designation by the Japanese health authorities.10